Compile Data Set for Download or QSAR
Report error Found 59 Enz. Inhib. hit(s) with all data for entry = 9079
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397792(US9994590, Compound 1 | US10604536, Compound 1)
Affinity DataIC50: 10nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397931(US9994590, Compound 3 | US10604536, Compound 3)
Affinity DataIC50: 10nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397957(US9994590, Compound 29 | US10604536, Compound 29)
Affinity DataIC50: 10nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397955(US9994590, Compound 27 | US10604536, Compound 27)
Affinity DataIC50: 10nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397977(US9994590, Compound 49 | US10604536, Compound 50)
Affinity DataIC50: 10nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397960(US9994590, Compound 32 | US10604536, Compound 32)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397958(US9994590, Compound 30 | US10604536, Compound 30)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397962(US9994590, Compound 34 | US10604536, Compound 34)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397963(US9994590, Compound 35 | US10604536, Compound 35)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397964(US9994590, Compound 36 | US10604536, Compound 36)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397965(US9994590, Compound 37 | US10604536, Compound 37)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397967(US9994590, Compound 39 | US10604536, Compound 39)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397949(US9994590, Compound 21 | US10604536, Compound 21)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397947(US9994590, Compound 19 | US10604536, Compound 19)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397972(US9994590, Compound 44 | US10604536, Compound 44)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397945(US9994590, Compound 17 | US10604536, Compound 17)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397943(US9994590, Compound 15 | US10604536, Compound 15)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397976(US9994590, Compound 48 | US10604536, Compound 48)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397979(US9994590, Compound 51 | US10604536, Compound 52)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397981(US9994590, Compound 53 | US10604536, Compound 54)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397983(US9994590, Compound 55 | US10604536, Compound 55)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397933(US9994590, Compound 5 | US10604536, Compound 5)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397984(US9994590, Compound 56 | US10604536, Compound 57)
Affinity DataIC50: 55nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397974(US9994590, Compound 46 | US10604536, Compound 46)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397975(US9994590, Compound 47 | US10604536, Compound 47)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397969(US9994590, Compound 41 | US10604536, Compound 41)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397977(US9994590, Compound 49 | US10604536, Compound 50)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397966(US9994590, Compound 38 | US10604536, Compound 38)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397979(US9994590, Compound 51 | US10604536, Compound 52)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397981(US9994590, Compound 53 | US10604536, Compound 54)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397961(US9994590, Compound 33 | US10604536, Compound 33)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397987(US9994590, Compound 59 | US10604536, Compound 59)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397956(US9994590, Compound 28 | US10604536, Compound 28)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397941(US9994590, Compound 13 | US10604536, Compound 13)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397934(US9994590, Compound 6 | US10604536, Compound 6)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397948(US9994590, Compound 20 | US10604536, Compound 20)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397950(US9994590, Compound 22 | US10604536, Compound 22)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397951(US9994590, Compound 23 | US10604536, Compound 23)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397959(US9994590, Compound 31 | US10604536, Compound 31)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397954(US9994590, Compound 26 | US10604536, Compound 26)
Affinity DataIC50: 300nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397952(US9994590, Compound 24 | US10604536, Compound 58)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397932(US9994590, Compound 4 | US10604536, Compound 4)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397984(US9994590, Compound 56 | US10604536, Compound 57)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397935(US9994590, Compound 7 | US10604536, Compound 7)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397936(US9994590, Compound 8 | US10604536, Compound 8)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397937(US9994590, Compound 9 | US10604536, Compound 9)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397938(US9994590, Compound 10 | US10604536, Compound 10)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397930(US9994590, Compound 2 | US10604536, Compound 2)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397939(US9994590, Compound 11 | US10604536, Compound 11)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharamaceuticals

US Patent
LigandPNGBDBM397940(US9994590, Compound 12 | US10604536, Compound 12)
Affinity DataIC50: 500nMAssay Description:The compounds were determined using the Molecular Devices IMAP PDE Fluorescence Polarization assay using recombinant human PDE-10 enzyme expressed in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 59 total ) | Next | Last >>
Jump to: